Brighten Optix Corporation (TPEX:6747)

Market Cap	5.41B
Revenue (ttm)	765.50M
Net Income (ttm)	67.74M
Shares Out	27.20M
EPS (ttm)	2.49
PE Ratio	79.80
Forward PE	n/a
Dividend	9.19 (4.62%)
Ex-Dividend Date	Apr 17, 2025

Volume	34,344
Average Volume	29,049
Open	198.50
Previous Close	199.00
Day's Range	198.50 - 199.00
52-Week Range	124.00 - 199.00
Beta	0.21
RSI	75.70
Earnings Date	Nov 13, 2025

About Brighten Optix

Brighten Optix Corporation researches, develops, manufactures, and sells contact lenses in Taiwan and internationally. The company offers orthokeratology, a non-invasive and reversible method of vision correction by using a hard contact lens to alter the shape of the front surface of the cornea; gas permeable lenses for single vison, multifocal, and irregular cornea and keratoconus correction, under the HiClear, So2clear, Menicon, Duette, ROSE K, Ampleye, MAXIM 3D, AND ULTRAHEALTH brand name; and soft contact lenses under the iDealsoft, Briomoi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1965
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6747

Financial Performance

In 2024, Brighten Optix's revenue was 766.93 million, an increase of 2.63% compared to the previous year's 747.30 million. Earnings were 149.79 million, a decrease of -24.82%.